The Technical AnalystExchange: MIL Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Pharmanutra S.p.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.39% €52.10
America/New_York / 3 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 500.94 mill |
| EPS: | 1.330 |
| P/E: | 39.17 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 9.61 mill |
| Avg Daily Volume: | 0.0052 mill |
| RATING 2024-05-03 |
|---|
| S |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.53x |
| Company: PE 39.17 | sector: PE 25.67 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.04x |
| Company: PE 39.17 | industry: PE 37.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€61.83 (18.67%) €9.73 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
€ 50.97 - 53.23 ( +/- 2.17%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €52.10 (0.39% ) |
| Volume | 0.0072 mill |
| Avg. Vol. | 0.0052 mill |
| % of Avg. Vol | 137.65 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PHN.MI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PHN.MI
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.